Us FDA approves Sotrovimab, a monoclonal antibody against Covid-19
US FDA approved Sotrovimab monoclonal antibodies for treatment of mild to moderate cases of covid 19 disease for age above 12 years old.
US FDA approved Sotrovimab monoclonal antibodies for treatment of mild to moderate cases of covid 19 disease for age above 12 years old.